Investigational drug · Phase 2
AZD2389
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Liver Fibrosis, Hepatic Cirrhosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "AZD2389"
First trial start
2024
Dec 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD2389", any sponsor or status.
Conditions studied
As listed on its trial records.
- Liver Fibrosis
- Hepatic Cirrhosis
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD2389" as an intervention, largest first.
- A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy ParticipantsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06138795 · 120 participants · Start Nov 20, 2023 · Primary completion Aug 24, 2025
Drug: AZD2389; Placebo · For: Healthy Participants
Sites: Glendale, California
- Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07610837 · 104 participants (planned) · Start May 7, 2026 · Primary completion Jul 7, 2027
Drug: AZD2389 · For: Liver Fibrosis; Hepatic Cirrhosis
Sites: Chandler, Arizona; Tucson, Arizona; Fresno, California · 22 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06750276 · 40 participants · Start Dec 6, 2024 · Primary completion Jul 28, 2025
Drug: AZD2389 · For: Liver Fibrosis; Hepatic Cirrhosis
Sites: Chandler, Arizona; Rialto, California; Atlanta, Georgia · 9 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06812780 · 35 participants · Start Feb 4, 2025 · Primary completion Sep 4, 2025
Drug: AZD2389 · For: Hepatic Impairment
Sites: Chandler, Arizona; Rialto, California; Miami Lakes, Florida · 5 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06974565 · 16 participants · Start May 12, 2025 · Primary completion Jul 18, 2025
Drug: AZD2389; Quinidine · For: Advanced Chronic Liver Disease; Healthy Participants
Sites: Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06846528 · 16 participants · Start Feb 26, 2025 · Primary completion Apr 23, 2025
Drug: AZD2389; Itraconazole · For: Healthy Participants
Sites: Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06973005 · 16 participants · Start May 8, 2025 · Primary completion Jul 18, 2025
Drug: AZD2389; Midazolam and 2 more · For: Advanced Chronic Liver Disease; Healthy Participants
Sites: Brooklyn, Maryland
AstraZenecaAstraZeneca (AZN)
NCT07069725 · 8 participants · Start May 26, 2025 · Primary completion Jul 2, 2026
Drug: AZD2389 · For: Liver Fibrosis; Hepatic Cirrhosis
Sites: Stockholm, Sweden
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Liver Fibrosis
- HydronidoneF351Phase 35 trials
Beijing Continent Pharmaceutical Co, Ltd. · Liver Fibrosis, Chronic Hepatitis B With Hepatic Fibrosis, Liver Fibrosis in Chronic Hepatitis B
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.